The Eating Disorder Examination Questionnaire (EDE-Q) is a self-report questionnaire that has been adapted from the Eating Disorder Examination (EDE). It can be completed individually or with the help of a clinician and consists of 41 items.
Find out more about Eating Disorder Examination Questionnaire
First used: 13 October 2021
Related TopicEating Disorders
The two most common eating disorders are anorexia nervosa and bulimia nervosa, affecting roughly 16 million people globally. Current medications have limited success in treating people with these disorders. Research with psychedelics including MDMA and psilocybin to treat these disorders is underway.
Related TrialsEvaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy
The primary aim of this study is to assess the safety and tolerability of one 25 mg dose of psilocybin in participants with anorexia nervosa based on adverse events (AEs), changes in vital signs, electrocardiograms (ECGs) and clinical laboratory tests. The secondary objectives are to explore the efficacy of a single 25 mg dose of psilocybin on eating disorder symptoms and behaviors, body image, anxiety, food related obsessions and rituals, and body weight.
Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study
The primary aim of this study is to assess the acceptability and efficacy of treating anorexia nervosa with psilocybin. The secondary aim of this study is to use Magnetic Resonance Imaging (MRI) and Electroencephalography (EEG) to examine the neuronal underpinnings of treatment with psilocybin in this patient group.
Effects of Psilocybin in Anorexia Nervosa
The investigators will also assess a number of exploratory measures related to eating disorder pathophysiology.